Liver screening finds a large burden in China

Among 25,736 community adults, 43.7% met a noninvasive threshold for steatotic liver disease and 4.4% had liver stiffness of at least 8 kPa; these are screening estimates, not biopsy diagnoses.

✓ Verified Source The Lancet Gastroenterology & Hepatology paper, verified against PubMed, Crossref and OpenAlex ⚑ Liver health

The 60-second version

Community VCTE screening in 25,736 Chinese adults found common steatosis and a smaller group above liver-stiffness thresholds.

Key points

  • 43.7% met the study's imaging threshold for steatotic liver disease.
  • 4.4% had stiffness ≥8 kPa, while 1.6% and 0.8% crossed the higher 10 and 12 kPa thresholds.
  • Obesity, diabetes, other metabolic risks and heavy alcohol use were associated with greater burden; viral hepatitis was linked to stiffness.
  • The baseline cross-sectional design cannot show progression or prove that community screening improves outcomes.

Verdict. The burden warrants targeted clinical assessment, but VCTE thresholds are screening signals rather than biopsy-confirmed diagnoses.

In a community sample of 25,736 adults in China, 43.7% met a noninvasive threshold for steatotic liver disease and 4.4% had liver stiffness of at least 8 kPa. The figures describe screening measurements, not biopsy-confirmed diagnoses.

CohortWho was measured and how

The CHESS-LiverHealth project enrolled community adults at 18 sites across 13 provincial-level regions. After predefined exclusions and quality checks, the baseline cross-sectional analysis included 25,736 people with a median age of 51.

Recruitment29,023 enrolled; 25,736 included after disease, data-completeness and VCTE-quality exclusions.
Liver stiffnessVibration-controlled transient elastography, with ≥8 kPa as the primary fibrosis threshold.
SteatosisControlled attenuation parameter ≥248 dB/m.
DesignCross-sectional baseline of a prospective cohort; no progression outcome yet.

PrevalenceFat accumulation was common; higher stiffness was less common

43.7%met the steatotic liver disease threshold
4.4%had liver stiffness ≥8 kPa
1.6%had liver stiffness ≥10 kPa
0.8%had liver stiffness ≥12 kPa

The 4.4% estimate represented 1,136 participants. The declining prevalence at 10 and 12 kPa shows why reporting the exact threshold matters: different cutoffs describe different levels of concern.

SubtypesMost steatotic liver disease met metabolic criteria

MASLD39.5% had steatosis with metabolic dysfunction criteria.
MetALD2.0% met combined metabolic and alcohol criteria.
ALD1.6% met alcohol-associated disease criteria.
All steatotic liver disease43.7% met the imaging threshold across categories.

Risk distributionObesity and diabetes marked higher-stiffness groups

Liver stiffness ≥8 kPa occurred in 10.7% of participants with obesity and 10.7% of those with type 2 diabetes. Metabolic risks and heavy alcohol use were independently associated with both elevated stiffness and steatosis; chronic viral hepatitis was associated with elevated stiffness.

LimitsA national burden estimate still has boundaries

  • 1. Cross-sectional: the study cannot yet show who progresses to cirrhosis or liver cancer.
  • 2. Noninvasive thresholds: VCTE is useful for triage but is not a biopsy result.
  • 3. Selection: participating communities and post-enrollment exclusions affect generalizability.
  • 4. Alcohol measurement: classification partly depends on reported consumption and an alcohol-use questionnaire.

TransparencyFunding and competing interests were reported

The paper lists Zhongda Hospital, Southeast University as funder. Several authors reported research grants, consulting, speaking, advisory roles, company ties or equipment support from health and pharmaceutical organizations; most authors declared no competing interests.

A screening threshold identifies who may need assessment; it is not the final diagnosis.

Bottom lineTarget risk assessment and interpret scans clinically

The study supports stronger attention to liver risk among people with metabolic disease, harmful alcohol use or viral hepatitis. A clinical pathway should combine history, laboratory risk scores and quality-controlled imaging, with specialist evaluation where appropriate. One scan should not be self-interpreted.